| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Privigen vs Vyvgart Hytrulo
Side-by-side clinical, coverage, and cost comparison for polyradiculoneuropathy, chronic inflammatory demyelinating.Deep comparison between: Privigen vs Vyvgart Hytrulo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyvgart Hytrulo has a higher rate of injection site reactions vs Privigen based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyvgart Hytrulo but not Privigen, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Privigen
Vyvgart Hytrulo
At A Glance
IV infusion
Every 3-4 weeks
Intravenous immunoglobulin (IVIG)
SC injection
Once weekly
FcRn blocker
Indications
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Dosing
Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency 200-800 mg/kg IV every 3-4 weeks.
Immune thrombocytopenic purpura 1 g/kg IV daily for 2 consecutive days (total dose 2 g/kg).
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Loading dose: 2 g/kg IV in divided doses over 2-5 consecutive days; maintenance dose: 1 g/kg IV every 3 weeks.
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Contraindications
- History of anaphylactic or severe systemic reaction to human immune globulin
- Hyperprolinemia (product contains L-proline stabilizer)
- IgA deficiency with antibodies to IgA and a history of hypersensitivity
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
Adverse Reactions
Most common (>5%) Headache, fatigue, nausea, chills, vomiting, back pain, elevated body temperature, diarrhea, cough, stomach discomfort, asthenia, hypertension, pain in extremity, hemolysis, anemia, leukopenia, rash
Serious Hypersensitivity, aseptic meningitis syndrome, hemolysis, renal dysfunction and acute renal failure, thrombosis, hyperproteinemia, hyponatremia, volume overload, transfusion-related acute lung injury
Postmarketing Decreased neutrophil count, hemoglobinuria, renal failure, photophobia, cerebral edema, pruritus, cardiac arrest, thromboembolism, Stevens-Johnson syndrome, ARDS, seizures, hepatic dysfunction
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Pharmacology
PRIVIGEN is an intravenous immunoglobulin that supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents; the mechanism of action has not been fully elucidated but may include immunomodulatory effects.
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Privigen
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Privigen
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Privigen
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Privigen.
No savings programs available for Vyvgart Hytrulo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PrivigenView full Privigen profile
Vyvgart HytruloView full Vyvgart Hytrulo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.